US Patent

US11266622 — Method of treatment

Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2035-08-29 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating sleep disturbances in individuals with Smith-Magenis Syndrome.

USPTO Abstract

Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3003`	—
`U-3003`	—

Patent Metadata

Patent number: US11266622
Jurisdiction: US
Classification: Method of Use
Expires: 2035-08-29
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.